Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 11;36(7):1310-1326.
doi: 10.1681/ASN.0000000634.

PIEZO1-Mediated Calcium Signaling and Podocyte Injury in Diabetic Kidney Disease

Weiwei Li  1 , Zongwei Zhang  1   2   3 , Zhuan Peng  1 , Hongtu Hu  1 , Xiaofei Cui  1 , Zijing Zhu  1 , Yue Qi  1 , Wenjie Chen  1 , Hongyan Liu  1   2   3 , Wei Liang  1   2   3 , Guohua Ding  1   2   3 , Zhaowei Chen  1   2   3
Affiliations

PIEZO1-Mediated Calcium Signaling and Podocyte Injury in Diabetic Kidney Disease

Weiwei Li et al. J Am Soc Nephrol. .

Abstract

Key Points:

  1. Diabetic kidney disease progression was associated with increased Piezo1 expression in podocytes.

  2. Specific Piezo1 deletion alleviated podocyte injury in diabetic models.

  3. Piezo1 contributes to podocyte injury through nuclear factor of activated T cell cytoplasmic 1–transient receptor potential cation channel 6 signaling.

Background: Diabetic kidney disease (DKD) is characterized by progressive injury to glomerular podocytes due to sustained mechanical stress within the glomerulus. Piezo proteins, acting as cellular mechanosensors, play a pivotal role in mechanotransduction by sensing mechanical forces and regulating intracellular ion flux. This study investigates the role of Piezo1 in the progression of DKD and its mechanistic involvement in podocyte injury.

Methods: Podocyte-specific Piezo1 knockout mice were generated using the streptozotocin plus high-fat diet model of DKD. In vitro studies included the use of Piezo1 inhibitors to assess calcium influx, podocyte cytoskeletal rearrangement, and apoptosis under stiff matrix conditions. In addition, NF of activated T-cell cytoplasmic 1 (NFATc1) and transient receptor potential cation channel 6 (TRPC6) signaling pathways were explored to establish their role in Piezo1-mediated podocyte injury. Adeno-associated virus TRPC6 was used to overexpress TRPC6 in podocyte-specific Piezo1 knockout mice to assess the in vivo interaction between Piezo1 and TRPC6.

Results: Podocyte-specific deletion of Piezo1 significantly ameliorated the progression of DKD in diabetic mice. Inhibition of Piezo1 reduced calcium influx, cytoskeletal rearrangement, and podocyte apoptosis in vitro. Mechanistically, Piezo1 activation triggered a signaling loop involving NFATc1 and TRPC6, leading to increased calcium influx, perpetuating podocyte injury. TRPC6 overexpression in vivo counteracted the protective effects of Piezo1 deletion, confirming the critical role of the Piezo1/NFATc1/TRPC6 axis in DKD progression.

Conclusions: Piezo1 plays a key mechanosensory role in podocyte injury during DKD progression by mediating calcium influx and activating the NFATc1/TRPC6 signaling pathway.

Keywords: CKD; cell death; cell signaling; diabetic kidney disease; podocyte.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F73.

References

    1. Sun H Saeedi P Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119 - DOI - PMC - PubMed
    1. Edmonston D Lydon E Mulder H, et al. Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes. JAMA Netw Open. 2024;7(6):e2418808. doi: 10.1001/jamanetworkopen.2024.18808 - DOI - PMC - PubMed
    1. Van Raalte DH Bjornstad P Cherney DZI, et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. 2024;20(7):433–446. doi: 10.1038/s41581-024-00827-z - DOI - PubMed
    1. Meliambro K, He JC, Campbell KN. Podocyte-targeted therapies - progress and future directions. Nat Rev Nephrol. 2024;20(10):643–658. doi: 10.1038/s41581-024-00843-z - DOI - PubMed
    1. Yang H Sun J Sun A, et al. Podocyte programmed cell death in diabetic kidney disease: molecular mechanisms and therapeutic prospects. Biomed Pharmacother. 2024;177:117140. doi: 10.1016/j.biopha.2024.117140 - DOI - PubMed

LinkOut - more resources